vs
Guardant Health, Inc.（GH）与LiveRamp Holdings, Inc.（RAMP）财务数据对比。点击上方公司名可切换其他公司
Guardant Health, Inc.的季度营收约是LiveRamp Holdings, Inc.的1.3倍（$281.3M vs $212.2M），LiveRamp Holdings, Inc.净利率更高（18.8% vs -45.7%，领先64.5%），Guardant Health, Inc.同比增速更快（39.4% vs 8.6%），过去两年Guardant Health, Inc.的营收复合增速更高（29.2% vs 11.1%）
Guardant Health, Inc.是总部位于美国加利福尼亚州帕洛阿尔托的生物技术企业，由Helmy Eltoukhy与AmirAli Talasaz联合创立，目前二人共同出任公司首席执行官，统筹公司战略规划与日常运营管理工作。
LiveRamp Holdings, Inc.是一家美国SaaS企业，核心业务为提供数据连接平台，服务涵盖数据导入、线下数据线上迁移等能力，助力企业开展营销相关的数据应用，为品牌及营销从业者的数字化运营提供技术支撑。
GH vs RAMP — 直观对比
营收规模更大
GH
是对方的1.3倍
$212.2M
营收增速更快
GH
高出30.8%
8.6%
净利率更高
RAMP
高出64.5%
-45.7%
两年增速更快
GH
近两年复合增速
11.1%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $281.3M | $212.2M |
| 净利润 | $-128.5M | $39.9M |
| 毛利率 | 64.6% | 71.9% |
| 营业利润率 | -43.0% | 18.6% |
| 净利率 | -45.7% | 18.8% |
| 营收同比 | 39.4% | 8.6% |
| 净利润同比 | -15.8% | 255.7% |
| 每股收益（稀释后） | $-1.01 | $0.62 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GHRAMP
| Q4 25 | $281.3M | $212.2M | ||
| Q3 25 | $265.2M | $199.8M | ||
| Q2 25 | $232.1M | $194.8M | ||
| Q1 25 | $203.5M | $188.7M | ||
| Q4 24 | $201.8M | $195.4M | ||
| Q3 24 | $191.5M | $185.5M | ||
| Q2 24 | $177.2M | $176.0M | ||
| Q1 24 | $168.5M | $171.9M |
净利润GHRAMP
| Q4 25 | $-128.5M | $39.9M | ||
| Q3 25 | $-92.7M | $27.4M | ||
| Q2 25 | $-99.9M | $7.7M | ||
| Q1 25 | $-95.2M | $-6.3M | ||
| Q4 24 | $-111.0M | $11.2M | ||
| Q3 24 | $-107.8M | $1.7M | ||
| Q2 24 | $-102.6M | $-7.5M | ||
| Q1 24 | $-115.0M | $-5.4M |
毛利率GHRAMP
| Q4 25 | 64.6% | 71.9% | ||
| Q3 25 | 64.7% | 70.2% | ||
| Q2 25 | 65.0% | 70.1% | ||
| Q1 25 | 63.3% | 69.3% | ||
| Q4 24 | 61.6% | 71.9% | ||
| Q3 24 | 61.1% | 72.4% | ||
| Q2 24 | 59.1% | 70.6% | ||
| Q1 24 | 61.2% | 72.2% |
营业利润率GHRAMP
| Q4 25 | -43.0% | 18.6% | ||
| Q3 25 | -37.3% | 10.7% | ||
| Q2 25 | -45.9% | 3.7% | ||
| Q1 25 | -54.6% | -6.1% | ||
| Q4 24 | -62.4% | 7.5% | ||
| Q3 24 | -61.3% | 4.0% | ||
| Q2 24 | -56.8% | -3.0% | ||
| Q1 24 | -59.2% | -8.3% |
净利率GHRAMP
| Q4 25 | -45.7% | 18.8% | ||
| Q3 25 | -35.0% | 13.7% | ||
| Q2 25 | -43.0% | 4.0% | ||
| Q1 25 | -46.8% | -3.3% | ||
| Q4 24 | -55.0% | 5.7% | ||
| Q3 24 | -56.3% | 0.9% | ||
| Q2 24 | -57.9% | -4.3% | ||
| Q1 24 | -68.2% | -3.1% |
每股收益（稀释后）GHRAMP
| Q4 25 | $-1.01 | $0.62 | ||
| Q3 25 | $-0.74 | $0.42 | ||
| Q2 25 | $-0.80 | $0.12 | ||
| Q1 25 | $-0.77 | $-0.10 | ||
| Q4 24 | $-0.90 | $0.17 | ||
| Q3 24 | $-0.88 | $0.03 | ||
| Q2 24 | $-0.84 | $-0.11 | ||
| Q1 24 | $-0.94 | $-0.09 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $378.2M | $403.4M |
| 总债务越低越好 | $1.5B | — |
| 股东权益账面价值 | $-99.3M | $962.3M |
| 总资产 | $2.0B | $1.3B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GHRAMP
| Q4 25 | $378.2M | $403.4M | ||
| Q3 25 | $580.0M | $376.9M | ||
| Q2 25 | $629.1M | $371.1M | ||
| Q1 25 | $698.6M | $420.8M | ||
| Q4 24 | $525.5M | $384.3M | ||
| Q3 24 | $585.0M | $348.4M | ||
| Q2 24 | $933.7M | $342.7M | ||
| Q1 24 | $1.0B | $368.9M |
总债务GHRAMP
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益GHRAMP
| Q4 25 | $-99.3M | $962.3M | ||
| Q3 25 | $-354.5M | $943.8M | ||
| Q2 25 | $-305.5M | $947.8M | ||
| Q1 25 | $-250.8M | $948.9M | ||
| Q4 24 | $-139.6M | $957.7M | ||
| Q3 24 | $-60.1M | $932.1M | ||
| Q2 24 | $-1.6M | $951.9M | ||
| Q1 24 | $68.3M | $949.1M |
总资产GHRAMP
| Q4 25 | $2.0B | $1.3B | ||
| Q3 25 | $1.3B | $1.2B | ||
| Q2 25 | $1.3B | $1.2B | ||
| Q1 25 | $1.3B | $1.3B | ||
| Q4 24 | $1.5B | $1.3B | ||
| Q3 24 | $1.5B | $1.2B | ||
| Q2 24 | $1.6B | $1.2B | ||
| Q1 24 | $1.7B | $1.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-26.4M | — |
| 自由现金流经营现金流 - 资本支出 | $-54.2M | — |
| 自由现金流率自由现金流/营收 | -19.3% | — |
| 资本支出强度资本支出/营收 | 9.9% | 0.1% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-233.1M | — |
8季度趋势，按日历期对齐
经营现金流GHRAMP
| Q4 25 | $-26.4M | — | ||
| Q3 25 | $-35.4M | $57.4M | ||
| Q2 25 | $-60.3M | $-15.8M | ||
| Q1 25 | $-62.7M | — | ||
| Q4 24 | $-64.5M | $45.1M | ||
| Q3 24 | $-51.1M | $55.6M | ||
| Q2 24 | $-94.0M | $-9.3M | ||
| Q1 24 | $-30.3M | — |
自由现金流GHRAMP
| Q4 25 | $-54.2M | — | ||
| Q3 25 | $-45.8M | $56.8M | ||
| Q2 25 | $-65.9M | $-16.2M | ||
| Q1 25 | $-67.1M | — | ||
| Q4 24 | $-83.4M | $44.8M | ||
| Q3 24 | $-55.3M | $55.4M | ||
| Q2 24 | $-99.1M | $-9.6M | ||
| Q1 24 | $-37.2M | — |
自由现金流率GHRAMP
| Q4 25 | -19.3% | — | ||
| Q3 25 | -17.3% | 28.4% | ||
| Q2 25 | -28.4% | -8.3% | ||
| Q1 25 | -33.0% | — | ||
| Q4 24 | -41.3% | 22.9% | ||
| Q3 24 | -28.9% | 29.8% | ||
| Q2 24 | -55.9% | -5.4% | ||
| Q1 24 | -22.1% | — |
资本支出强度GHRAMP
| Q4 25 | 9.9% | 0.1% | ||
| Q3 25 | 3.9% | 0.3% | ||
| Q2 25 | 2.4% | 0.2% | ||
| Q1 25 | 2.2% | 0.2% | ||
| Q4 24 | 9.4% | 0.1% | ||
| Q3 24 | 2.2% | 0.1% | ||
| Q2 24 | 2.9% | 0.1% | ||
| Q1 24 | 4.1% | 1.0% |
现金转化率GHRAMP
| Q4 25 | — | — | ||
| Q3 25 | — | 2.09× | ||
| Q2 25 | — | -2.04× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 4.02× | ||
| Q3 24 | — | 32.10× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
RAMP
暂无分部数据
